¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primary central nervous system lymphoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • primary amebic meningoencephalitis
    ¿ø¹ß¾Æ¸Þ¹Ù¼ö¸·³ú¿°
  • primary amenorrhea
    ¿ø¹ß¹«¿ù°æ
  • primary amnion
    ÀÏÂ÷¾ç¸·, ¿ø½Ã¾ç¸·
  • primary amyloidosis
    ¿ø¹ß¾Æ¹Ð·ÎÀ̵åÁõ
  • primary aqueous
    ÀÏÂ÷¹æ¼ö, ¿ø¹æ¼ö
  • primary atelectasis
    ¿ø¹ß¹«±âÆó
  • primary atypical pneumonia
    ¿ø¹ßºñÁ¤ÇüÆó·Å
  • primary biliary cirrhosis
    ¿ø¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • primary brain vesicles
    ÀÏÂ÷³úÆ÷
  • primary bronchus
    ÀÏÂ÷±â°üÁö
  • primary cancer
    ¿ø¹ß¾Ï
  • primary carcinoma
    ¿ø¹ß¾ÏÁ¾
  • primary cardiomyopathy
    ¿ø¹ß½ÉÀå±ÙÀ°º´(Áõ), ¿ø¹ß½É±Ùº´(Áõ)
  • primary cement
    ÀÏÂ÷½Ã¸àÆ®Áú
  • primary character
    ÀÏÂ÷¼º°Ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • primary character
    ÀÏÂ÷¼º°Ý
  • primary coil
    ÀÏÂ÷ÄÚÀÏ
  • primary complex
    Ãʱ⺯ȭ±º, ¿ø¹ßº¹ÇÕü
  • primary constriction
    (¢¡centromere) ¸Åµì, µ¿¿øÃ¼, Áß½ÉÀý
  • primary contact
    ÀÏÂ÷Á¢ÃË
  • primary culture
    óÀ½½É±â
  • primary biliary cirrhosis
    ¿ø¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • primary health care
    ÀÏÂ÷º¸°ÇÀÇ·á
  • primary inoculation complex
    ¿ø¹ßÁ¢Á¾º¹ÇÕü
  • primary ossification center
    ÀÏÂ÷»ÀµÇ±âÁß½É, ÀÏÂ÷°ñÈ­Áß½É
  • primary sex character
    ÀÏÂ÷¼ºÂ¡
  • delayed primary suture
    Áö¿¬ÀÏÂ÷ºÀÇÕ
  • primary dentin
    ÀÏÂ÷»ó¾ÆÁú
  • primary dentition
    (¢¡deciduous tooth) Á¥´Ï, Å»¶ôÄ¡¾Æ
  • primary depression
    ÀÏÂ÷¿ì¿ïÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • gate control system
    °ü¹®Á¶Á¤ÀåÄ¡(μڦðàïÚíûöÇ).
  • general system theory
    ÀϹÝü°è(ÀÌ)·Ð(ìéÚõô÷ͧìµÖå)
  • genital system
    »ý½Ä°è(ßæãÖͧ).
  • genital system
    »ý½Ä°èÅë
  • genital system
    »ý½Ä±â°è(ßæãÖÐïͧ)
  • genitourinary system
    ºñ´¢»ý½Ä±â°èÅë(ù²èñßæãÖÐïͧ÷Ö).
  • genitourinary system
    ºñ´¢»ý½Ä±â°èÅë(ù²èñßæãÖÐïͧ÷Ö).
  • global budget system
    ÃѾ׿¹»êÁ¦, ÃѾװè¾àÁ¦.
  • guarantee system
    º¸ÁõÁ¦µµ(ËÓ̡̡̬).
  • h2o2-myeloperxidase-halide system
    °ú»êÈ­¼ö¼Ò-°ñ¼ö°ú»êÈ­È¿¼Ò-ÇÒ·Î°Õ °èÅë
  • hamatopoietic system
    Á¶Ç÷±â°ü(ðãúìÐïί)
  • health care delivery system
    ÀÇ·áÀü´ÞÁ¦µµ(ËöËíËøËÀ̡̬).
  • health care system
    º¸°ÇÀÇ·áü°è.
  • health information system
    º¸°ÇÁ¤º¸Ã¼°è.
  • heterogeneous system
    ºÒ±ÕÀϰè, ºÒ±ÕÁú°è.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • nervous headache
    ½Å°æ¼º µÎÅë(~Ôé÷Ô).
  • nervous layer
    ½Å°æÃþ
  • nervous lesion
    ½Å°æ°èº´º¯.
  • nervous papilla
    ½Å°æÀ¯µÎ(~êáÔé).
  • nervous paralysis
    ½Å°æ¼º ¸¶ºñ.
  • nervous tissue
    ½Å°æÁ¶Á÷(~ðÚòÄ).
  • nervous tissue
    ½Å°æÁ¶Á÷
  • nervous tissue (neuroblastoma)
    ½Å°æÁ¶Á÷ (½Å°æ¸ð¼¼Æ÷Á¾)
  • nervous zygomaticotemporaris
    ±Ç°ñÃøµÎ½Å°æ, Çù°ñÃøµÎ½Å°æ.
  • nervous ³ª nervosus
  • oculomotor nervous branch
    ´«µ¹¸²½Å°æ°¡Áö
  • reactive nervous state
    ¹ÝÀÀ¼º ½Å°æ°ú¹Î»óÅÂ(ÚãëëàõãêÌèΦÚÂßÒ÷¾).
  • somatic nervous systema
    ü(¼º)½Å°æ°è(ô÷àõãêÌèÍ£).
  • subepidermal nervous plexus
    Ç¥ÇÇÇÏ ½Å°æ ¾ó±â
  • submucous nervous plexus
    Á¡¸·¹Ø½Å°æ¾ó±â
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Central fovea
    Á߽ɿÀ¸ñ
    [¿¾ ¿ë¾î] Á߽ɿÍ
  • Central vein
    Áß½ÉÁ¤¸Æ
    [¿¾ ¿ë¾î] Áß½ÉÁ¤¸Æ
  • Central veins
    Áß½ÉÁ¤¸Æ
    [¿¾ ¿ë¾î] Áß½ÉÁ¤¸Æ
  • Central intermediate substance
    Áß½ÉÁß°£È¸»öÁú
    [¿¾ ¿ë¾î] Áß°£ÁúÁ߽ɺÎ
  • Central nucleus
    Áß½ÉÇÙ
    [¿¾ ¿ë¾î] Áß½ÉÇÙ
  • Central gray (substance)
    Áß½Éȸ»öÁú
    [¿¾ ¿ë¾î] Áß½Éȸ¹éÁú
  • Central glial cell
    ÁßÃ߾Ʊ³¼¼Æ÷
    [¿¾ ¿ë¾î] Á߽ɽŰ汳¼¼Æ÷
  • Short central artery
    ªÀºÁ߽ɵ¿¸Æ
    [¿¾ ¿ë¾î] ´ÜÁ߽ɵ¿¸Æ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • T system
    T ½Ã½ºÅÛ
  • V system
    V ½Ã½ºÅÛ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
CNE chief nurse executive; chronic nervous exhaustion; concentric needle electrode
CNES chronic nervous exhaustion syndrome
ner nervous
CIS carcinoma in situ; catheter-induced spasm; central inhibitory state; Chemical Information Service; c...
PCM patient care manager or management; patient classification system; primary cutaneous melanoma; proce...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
CSCR Central Serous Chorioretinopathy
C.S.R. Central Serous Retinopathy
CVC Central Venous Catheter
CEE Central and Eastern Europe
CBV Central blood volume
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • central serous choroidopathy
    Á߽ɼº Àå¾× ¸Æ¶ô¸·º´Áõ
  • central somatosensory pathway
    ÁßÃß¼º ü¼º °¨°¢ °æ·Î, ÁßÃß Ã¼¼º °¨°¢ °æ·Î
  • central spindle
    Á᫐ ¹æÃß
  • central suppression
    ÁßÃß¼º ¾ïÁ¦, Á᫐ ¾ïÁ¦
  • central tegmental tract
    Á᫐ µÚÆÇ·Î
  • central transmission
    ÁßÃß Àü´Þ
  • central trigeminal sensory pathway
    ÁßÃß¼º »ïÂ÷ ½Å°æ °¨°¢Áö °æ·Î, Á߽ɼº »ïÂ÷ ½Å°æ °¨°¢Áö °æ·Î
  • central vein nutritional support
    Á᫐ Á¤¸Æ ¿µ¾ç ÁöÁö ¿ä¹ý
    ¹«±Õ ±â¼úÀ» »ç¿ëÇÏ¿© °æÇÇÀûÀ¸·Î À§Ä¡ÇÑ Á¤¸Æ³» µµ°üÀ» ÅëÇØ °¡Àå ÈçÈ÷ ÀüÇØÁø´Ù. »ó´ë Á¤¸ÆÀ¸·ÎÀÇ ÀûÀýÇÑ ¹èÄ¡´Â ¿ë¾×ÀÇ Åõ¿©¸¦ ½ÃÀÛÇϱâ Àü¿¡ ¹æ»ç¼±ÇÐÀûÀ¸·Î Áõ¸íµÈ´Ù. µµ°üÀº °æÇèÀÌ ÀÖ´Â °£È£ ¿ä¿ø¿¡ ÀÇÇØ Á¶½É½º·´°Ô À¯ÁöµÇ°í ¿µ¾ç ÁöÁö ¿ä¹ý À̿ܿ¡´Â »ç¿ëµÇÁö ¾Ê¾Æ¾ß ÇÑ´Ù.
  • central venous pressure
    Á᫐ Á¤¸Æ¾Ð
    ¿ì½É¹æ¿¡¼­ ÃøÁ¤ÇÑ Á¤¸Æ¾Ð. »óÇà ´ëÁ¤¸Æ³»·Î Ä«Å×Å͸¦ Á¤Áß ÁÖ Á¤¸ÆÀ» ÅëÇØ »ðÀÔÇÏ°í ±× ³¡¿¡ ¾Ð·Â°è¸¦ ºÎÂøÇÏ¿© ÃøÁ¤ÇÑ´Ù. ü¼øÈ¯°èÀÇ ¸ðµç Á¤¸Æ Ç÷¾×Àº ¿ì½É¹æÀ¸·Î Èê·¯µé¹Ç·Î ¿ì½É¹æ³»ÀÇ ¾Ð·ÂÀ» Á᫐ Á¤¸Æ¾ÐÀ̶ó°í ÇÑ´Ù. ¸»ÃÊ Á¤¸Æ Ç÷¾ÐÀº ÀÌ Á᫐ Á¤¸Æ Ç÷¾ÐÀÇ º¯È­¿¡ µû¶ó º¯ÇÑ´Ù.
  • central visual acuity
    Á᫐ ½Ã·Â
  • deafferented central neuron
    ±¸½É·Î Â÷´Ü Á߽ɼº ´º¿ì·±
  • deciduous central incisor
    À¯ÁßÀýÄ¡
  • lower central incisor
    ÇÏ¾Ç ÁßÀýÄ¡
    Ä¡±Ã¿¡¼­ °¡Àå ÀÛÀº Ä¡¾Æ·Î »ó¾Ç ÀýÄ¡¿Í ´Þ¸® ¼ø¼³°æÀÌ ±Ù¿ø½É°æ º¸´Ù ´õ ±»Àº ÇüÅÂÀ̸ç Àý´Ü¸éÀÌ Ä¡°üÀÇ ¼ø¼³Æø Áß¾Ó¿¡¼­ ¾à°£ ¼³ÃøÀ¸·Î Ä¡¿ìÃÄ ÀÖ°í »ó¾Ç ÁßÀýÄ¡¿Í 1Ä¡´ë 1Ä¡ÀÇ °ü°è¸¦ °®°í ÀÖ°í Ä¡°üÀÇ ±Ù, ¿ø½É¹ÝºÎ°¡ °ÅÀÇ ´ëĪÀ» ÀÌ·ç°í ÀÖ¾î ÁÂ, ¿ìÃø ±¸º°ÀÌ °¡Àå ¾î·Á¿î Ä¡¾ÆÀÌ´Ù.
  • upper central incisor
    »ó¾Ç ÁßÀýÄ¡
  • A alpha primary afferent
    A ¾ËÆÄ ÀÏÂ÷ ±¸½É ½Å°æ
    ±Ù¹æÃß ³»ÀÇ ±Ù ¼¶À¯¿¡ Á¸ÀçÇÏ´Â °¨°¢½Å°æÀÇ Çϳª·Î ¥°a °¨°¢ ½Å°æÀ̶ó°íµµ ÇÑ´Ù. Á÷°æÀº 22§­, Àüµµ ¼Óµµ´Â 120§½ÀÌ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
lymphoma, large-cell, ki-1 A large-cell, non-hodgkin's, malignant lymphoma with pleomorphic appearance and reactivity with the monoclonal antibody ki-1. The lymphoma is most often found in the skin and lymph nodes and expresses the ki-1 (CD30) antigen (antigens, CD30) on its surface. It is often mistaken for metastatic carcinoma and malignant histiocytosis.
(12 Dec 1998)
lymphoma, low-grade One of the three major prognostic groupings for non-hodgkin lymphomas as proposed in the working formulation of the non-hodgkin's lymphoma pathologic classification project sponsored by the national cancer institute (1981). Lymphomas falling within this group have a relatively favourable survival potential.
(12 Dec 1998)
lymphoma, lymphoblastic A high-grade malignant lymphoma composed of a diffuse, relatively uniform proliferation of cells with round or convoluted nuclei and scanty cytoplasm. The cells are cytologically similar to the lymphoblasts seen in acute lymphocytic leukaemia, and in some cases, the disease may evolve into a leukaemic phase morphologically indistinguishable from acute t-lymphocytic leukaemia (leukaemia, T-cell, acute). Lymphoblastic lymphoma represents approximately one-third of the cases of non-hodgkin's lymphomas in children and 5% of the cases in adults. It is more prevalent in males.
(12 Dec 1998)
lymphoma, mixed-cell Malignant lymphoma characterised by the presence of a mixed population of cells, with the smaller cells resembling lymphocytes and the larger ones histiocytes. It usually presents in a nodular (follicular) pattern, but may evolve into a diffuse pattern.
(12 Dec 1998)
lymphoma, mixed-cell, diffuse A heterogeneous group of intermediate-grade lymphomas of mixed cellular composition. Although they have not been extensively studied, it appears that they are predominantly B-cell diseases.
(12 Dec 1998)
lymphoma, mixed-cell, follicular A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.
(12 Dec 1998)
lymphoma, mucosa-associated lymphoid tissue Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire malt tissue as a result of an immunologically mediated disorder.
(12 Dec 1998)
lymphoma, non-hodgkin Any of a group of malignant tumours of lymphoid tissue that differ from hodgkin disease, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumours is the absence of giant reed-sternberg cells, a characteristic of hodgkin's disease.
(12 Dec 1998)
lymphoma, small-cell A B-cell lymphoma presumably representing a tumour of interfollicular B-lymphocytes that may be functional. Those that are secrete identical immunoglobulin molecules.
(12 Dec 1998)
lymphoma, small cleaved-cell, diffuse An intermediate-grade malignant lymphoma in which the neoplastic cells (B-lymphocytes) exhibit variability in size, configuration, and degree of differentiation. The cells have distinctive nuclei, irregular in shape, with marked indentations and angularity.
(12 Dec 1998)
lymphoma, small cleaved-cell, follicular A low-grade malignant lymphoma of predominantly follicular pattern. Follicles are of relatively uniform size and shape and the cells are usually somewhat larger than normal lymphocytes. Nuclei are irregular with prominent indentations and cytoplasm can rarely be identified. Cells exhibiting these characteristics are often called centrocytes.
(12 Dec 1998)
lymphoma, small lymphocytic A low-grade malignant lymphoma that may, in some cases, be considered histologically identical to chronic lymphocytic leukaemia (cll; leukaemia, lymphocytic, chronic). It is diffuse in pattern, representing the neoplastic proliferation of well-differentiated B-lymphocytes. In patients with immunoglobulin gammopathies, the lymphocytes may exhibit plasmacytoid characteristics.
(12 Dec 1998)
lymphoma, small noncleaved-cell A high-grade malignant lymphoma that includes both burkitt tumour (burkitt lymphoma) and other lymphomas previously designated undifferentiated non-burkitt type. Nuclei in burkitt tumour are round to ovoid and uniform in size. The non-burkitt type exhibits greater nuclear variation and less evidence of cellular maturation with a correspondingly lesser degree of differentiation.
(12 Dec 1998)
lymphoma, T-cell A group of heterogeneous lymphoid tumours representing malignant transformations of T-lymphocytes.
(12 Dec 1998)
lymphoma, T-cell, cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. Mycosis fungoides and sezary syndrome are the best characterised of these disorders.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • convict system
    ¡¿ª(À¯Çü)Á¦µµ
  • coupon system
    °æÇ°ºÎ ÆÇ¸Å¹ý
  • data base management system
    (Àü»ê)µ¥ÀÌÅͺ£À̽º °ü¸® ½Ã½ºÅÛ(¾à DBMS)
  • decimal system
    ½ÊÁø¹ý
  • decision support system
    (Àü»ê)(°æ¿µÀÇ)ÀÇ»ç °áÁ¤ Áö¿ø ½Ã½ºÅÛ
  • delayed time system
    (ÀüÀÚ)½Ã°£ Áö¿¬(ÃàÀû)¹æ½Ä
  • digestive system
    (ÇØ)¼ÒÈ­±â °èÅë(ÀÔ,À§,Àå µî)
  • domestic system
    °¡³» °ø¾÷ Á¦µµ
  • duples system
    (Àü»ê)º¹½Ä ½Ã½ºÅÛ(2´ëÀÇ ÄÄÇ»Å͸¦ ¼³Ä¡Ç쵂 Çϳª´Â ¿¹ºñ¿ë)
  • early-warning system
    (±º)(ÇÙ°ø°Ý¿¡ ´ëÇÑ)Á¶±â °æº¸ Á¶Á÷
  • factory system
    °øÀå Á¦µµ
  • farm system
    Á¦2±º ¸®±× ÇÕµ¿ ¿î¿µÁ¦
  • feudal system
    ºÀ°Ç Á¦µµ
  • fixed exchange rate(system)
    °íÁ¤È¯½Ã¼¼(Á¦)
  • floating exchange rate system
    º¯µ¿ ȯÀ²Á¦
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á